Toremifene

This page contains recent news articles, when available, and an overview of Toremifene but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.

Overview:

Toremifene (when available)

Pharmacology and use:
Toremifene is an antineoplastic hormonal agent primarily used in the treatment of advanced breast cancer. Toremifene is a nonsteroidal agent that has demonstrated potent antiestrogenic properties in animal test systems. The antiestrogenic effects may be related to its ability to compete with estrogen for binding sites in target tissues such as breast. Toremifene inhibits the induction of rat mammary carcinoma induced by dimethylbenzanthracene (DMBA) and causes the regression of already established DMBA-induced tumors. In this rat model, Toremifene appears to exert its antitumor effects by binding the estrogen receptors. In cytosols derived from human breast adenocarcinomas, Toremifene competes with estradiol for estrogen receptor protein. For the treatment of metastatic breast cancer in postmenopausal women with estrogen receptor-positive or receptor-unknown tumors

Mechanism Of Action:
Toremifene is a nonsteroidal triphenylethylene derivative. Toremifene binds to estrogen receptors and may exert estrogenic, antiestrogenic, or both activities, depending upon the duration of treatment, animal species, gender, target organ, or endpoint selected. The antitumor effect of toremifene in breast cancer is believed to be mainly due to its antiestrogenic effects, ie, its ability to compete with estrogen for binding sites in the cancer, blocking the growth-stimulating effects of estrogen in the tumor.

News Articles on Toremifene

GTx Presents Bone Turnover Marker Data and Additional PSA ...  -  16 Sep 2008
GTx, Inc. (Nasdaq: GTXI) today presented a safety analysis demonstrating that fewer men treated with toremifene 80 mg had PSA progression over time compared WELT ONLINE,

GTXI: Additional PSA Progression Safety Analysisfrom Ph III Trial ...  -  16 Sep 2008
GTx, Inc. (GTXI) presented a safety analysis today demonstrating that fewer men treated with toremifene 80 mg had PSA progression over time compared to Trading Markets (press release),

GTx to Present Additional Efficacy and Safety Analyses from the ...  -  Sep 10, 2008
GTx, Inc. (Nasdaq: GTXI) announced that additional efficacy and safety analyses from the Phase III clinical trial evaluating toremifene 80 mg for the Ad-Hoc-News (Pressemitteilung),

GTx to Present Additional  -  Sep 10, 2008
GTx, Inc. (Nasdaq: GTXI) announced that additional efficacy and safety analyses from the Phase III clinical trial evaluating toremifene 80 mg for the Ad-Hoc-News (Pressemitteilung),

GTx, Inc. Q2 2008 Earnings Call Transcript  -  Sep 8, 2008
In the second quarter we continue to make good progress towards the filing of the new drug application and planning the commercialization for toremifene 80 Seeking Alpha,

GTx, Inc. (GTXI) Chief Executive Officer to Ring the NASDAQ Stock ...  -  Aug 29, 2008
GTx is developing toremifene citrate, a selective estrogen receptor modulator, or SERM, in two separate clinical programs in men: first, a completed pivotal MarketWatch

INTERVIEW-GTx says muscle drug holds promise  -  Sep 2, 2008
CEO Mitchell Steiner said Ostarine has greater sales potential than GTx' best-known experimental drug, toremifene, now in late-stage studies, and intended Forbes,

-- Standalone(1) 2008 financial objectives raised  -  Aug 28, 2008
Ipsen also announced its intention to submit the toremifene citrate 80 mg dossier in Europe before year-end 2008. -- On February 21, 2008 -- Ipsen announced MarketWatch

Market Report -- In Play (WIRES)  -  Sep 10, 2008
On The Wires GTx (GTXI) announces that additional efficacy and safety analyses from the Phase III clinical trial evaluating toremifene 80 mg for the MSN Money

GTx loses more than $13M in 2Q  -  Aug 5, 2008
...because of pre-clinical and clinical programs, including the planned filing of a new drug application for the 80 milligram dosage of Toremifene. Bizjournals.com,

GTx Announces Phase III Clinical Development Of Toremifene 20 Mg ...  -  Jul 30, 2008
The DSMB meets every six months to review unblinded safety data from the toremifene Phase III clinical trials. "The DSMB has now reviewed safety data of the Medical News Today (press release),

GTx: Phase III Development of Toremifene on Course  -  Jul 30, 2008
...pivotal Phase III trial evaluating toremifene 20 mg as a prevention of prostate cancer in men with high-grade prostatic intraepithelial neoplasia (PIN). FDA news (subscription),

GTx clinical trial cleared by safety board  -  Jul 28, 2008
GTx Inc. will continue its Phase III clinical trial of prostate cancer drug toremifene after the trial cleared a planned safety review by an independent Bizjournals.com,

GTx 2Q loss widens on R&D, administrative costs  -  Aug 5, 2008
The company said it is continuing development of toremifene for the prevention of fractures and treatment of other estrogen related serious side effects of Forbes,

GTx receives positive review for Phase III prostate cancer study  -  Jul 30, 2008
By Staff Writer The data safety monitoring board meets every six months to review unblinded safety data from the toremifene Phase III clinical trials. Pharmaceutical Business Review

SmallCapReview - Small Cap Stocks to Watch - EXEL, ILOG  -  Jul 28, 2008
The DSMB meets every six months to review unblinded safety data from the toremifene Phase III clinical trials. What They Do: GTx, Inc., TransWorldNews (press release),

*vwd/BUSINESS WIRE: Ipsen’s First Half 2008 Sales, Outlook for the ...  -  Jul 30, 2008
On February 25, 2008 – Ipsen announced that GTx Inc., from which it licensed the European rights for Acapodene^® (toremifene citrate 80 mg) in September ddp-direkt.de,

Market Report -- In Play (GTXI)  -  Jul 28, 2008
GTx announces Ph. III clinical development of toremifene 20 mg on course following planned safety review Co announces that following a planned safety review MSN Money

GTXI: Data Safety Monitoring Board Recommends Continuation of Ph ...  -  Jul 28, 2008
III clinical trial evaluating toremifene 20 mg for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia (PIN). Trading Markets (press release),

Male Infertility  -  Jun 12, 2008
Toremifene Improves Sperm Quality in Men With Oligozoospermia Administration of the selective estrogen receptor modulator (SERM) toremifene has beneficial Medscape (subscription)

State-of-the-Art Lecture: What Are The Most Important Ongoing ...  -  Jun 23, 2008
He applauded prevention trials such as PCPT, SELECT, Toremifene for PIN and REDUCE. He gave poor marks for randomized treatment trials. Medical News Today (press release),

Fareston® Decreases Spinal Fractures in Men with Prostate Cancer  -  Jun 10, 2008
Among prostate cancer patients receiving androgen deprivation therapy (ADT), treatment with Fareston® (toremifene citrate) reduces the risk of new spinal Cancer Consultants,

GTx to continue Phase III study of toremifene 20 mg in prostrate ...  -  May 23, 2008
The three-year study evaluating toremifene 20 mg in men with high grade prostatic intraepithelial neoplasia, or PIN, has enrolled 1590 men with high grade RTT News,

GTx, Inc. Reports First Quarter 2008 Financial Results  -  May 12, 2008
..."Our first quarter announcement that the toremifene 80 mg Phase III ADT clinical trial met its primary endpoint was a transformational event for GTx,�? said WELT ONLINE,

GTx Appoints Kenneth S. Robinson, MD to the Board of Directors  -  May 6, 2008
In 2006, GTx and Ipsen Group entered into a development and collaboration agreement for toremifene citrate in all indications except breast cancer for FOXBusiness

GTx Announces Phase III PIN Clinical Trial Will Continue As Planned  -  May 27, 2008
GTx, Inc. (Nasdaq: GTXI) today announced that an independent biometrics group recommended that the Phase III clinical trial evaluating toremifene 20 mg in Centre Daily Times,

GTx to continue Phase III prostatic neoplasia trial  -  May 26, 2008
GTx will make a final determination about the toremifene 20mg Phase III clinical trial after an efficacy analysis in the summer of 2009. Pharmaceutical Business Review

GTx Prostate Cancer Trial Will Continue as Planned  -  May 27, 2008
The three-year, double-blind, placebo-controlled trial in 1590 randomized men is evaluating toremifene 20 mg in patients with high-grade prostatic FDA news (subscription),

GTX Inc. Drops In Pre-Market To Hit 2-Month Low  -  May 23, 2008
Further, the company announced that an independent biometrics group recommended the Phase III clinical trial, evaluating toremifene 20 mg in men with high RTT News,

The Maybach Financial Group: GTx Announces Phase III PIN Clinical ...  -  May 24, 2008
GTx will make a final determination about the toremifene 20 mg Phase III clinical trial after an efficacy analysis in the summer of 2009. Trading Markets (press release),

Market Report -- In Play (GTXI)  -  May 23, 2008
...independent biometrics group recommended that the Phase III clinical trial evaluating toremifene 20 mg in men with high grade prostatic intraepithelial MSN Money

Toremifene reduced fractures in androgen-deprivation-treated ...  -  Apr 16, 2008
SAN DIEGO — Toremifene at 80 mg significantly decreased new morphometric vertebral fractures in men receiving androgen deprivation therapy for prostate Endocrine Today,

GTx Announces Upcoming Presentation of Toremifene Citrate 80 mg ...  -  Apr 8, 2008
...“A Phase III randomized controlled trial of toremifene to prevent fractures and other adverse effects of androgen therapy in men with prostate cancer. Business Wire (press release),

First Fracture Prevention Study in Men Receiving ADT for Prostate ...  -  Apr 15, 2008
Results of the Phase III ADT clinical trial demonstrate that toremifene citrate 80 mg compared to placebo built bone and prevented fractures, Earthtimes,

GTx reports positive data from Phase III androgen deprivation ...  -  Apr 16, 2008
By Staff Writer Results of the Phase III androgen deprivation therapy (ADT) clinical trial demonstrate that toremifene citrate 80mg compared to placebo Pharmaceutical Business Review

GTX Corp. Hires Jb Bittner Eriksen As Chief Technology Officer ...  -  Apr 8, 2008
4/8/2008 6:45:47 AM GTx, Inc. (GTXI) announced that the results of the Phase III clinical trial evaluating toremifene citrate 80 mg will be presented during RTT News,

GTx, Inc.: A Diamond in a Mud Pit  -  Apr 2, 2008
One of the company’s most promising late-stage medicines is toremifene citrate, or Acapodene. It is used to help treat patients with advanced prostate Seeking Alpha,

Brand Names/Synonyms:
Toremifene is also known by the following brand names and/or synonymsAcapodene; Fareston; Farestone; Toremifene; Toremifene Base; Toremifeno [Spanish]; Toremifenum [Latin]; Z-Toremifene

Drug Category:
Toremifene is categorized under the following by the FDA: Antineoplastic Agents; Selective Estrogen Receptor Modulators; ATC:L02BA02

Dosage Forms:
Tablet

Absorption:
Well absorbed

Interactions:
Interactions for Toremifene:

Drugs that decrease renal calcium excretion, eg, thiazide diuretics, may increase the risk of hypercalcemia in patients receiving FARESTON. There is a known interaction between antiestrogenic compounds of the triphenylethylene derivative class and coumarin-type anticoagulants (eg, warfarin), leading to an increased prothrombin time. When concomitant use of anticoagulants with FARESTON is necessary, careful monitoring of the prothrombin time is recommended.

Cytochrome P450 3A4 enzyme inducers, such as phenobarbital, phenytoin, and carbamazepine increase the rate of toremifene metabolism, lowering the steady-state concentration in serum. Metabolism of toremifene may be inhibited by drugs known to inhibit the CYP3A4-6 enzymes. Examples of such drugs are ketoconazole and similar antimycotics as well as erythromycin and similar macrolides. This interaction has not been studied and its clinical relevance is uncertain.

Chemical IUPAC Name:
2-[4-(4-chloro-1,2-diphenyl-but-1-enyl)phenoxy]-N,N-dimethyl-ethanamine

:

Web health.mongabay.com

Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on health.mongabay.com lead to other sites. health.mongabay.com does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is health.mongabay.com responsible for dead or misdirected links.